Platelet Larger Cell Ratio and High-on Treatment Platelet Reactivity During Dual Antiplatelet Therapy
Low response to antiplatelet agents has been associated to an increased risk of thrombotic complications and recurrent ischemic events. Platelet size has been proposed as a potential marker of platelet reactivity. Therefore, the aim of the present study was to evaluate the impact of platelet Larger Cell Ratio (p-LCR) on platelet aggregation and the prevalence of residual high-on treatment platelet reactivity (HRPR) in patients receiving dual antiplatelet therapy (DAPT) after a recent acute coronary syndrome or coronary revascularization.
Patients treated with DAPT (ASA and clopidogrel or ticagrelor) were scheduled for platelet function assessment at 30–90 days post-discharge. HRPR was considered for ASPI test >862 AU*min (for ASA) or ADP test values ≥417 AU*min (for ADP-antagonists) using impedance aggregometry.
Our population consisted of 530 patients receiving DAPT, who were divided in tertiles according to values of p-LCR (< 27.6; 27.6–34.7; ≥34.7 l). p-LCR was related with use of beta-blockers (p = 0.02) and statins (p = 0.002), and inversely with acute presentation (p = 0.05). Higher platelet count (p < 0.001) and haemoglobin levels (p = 0.001) were observed in higher p-LCR tertiles.
The prevalence of HRPR for ASA was low and not significantly different across tertiles of p-LCR (1.1 vs 1.1 vs 1.7 %, p = 0.66; adjusted OR[95%CI] = 1.68[0.66–4.29], p = 0.27).
Moreover, p-LCR did not influence the occurrence of HRPR for ADP-antagonists (24.4 % vs 20.9 % vs 25.6 %%, p = 0.80, adjusted OR[95%CI] = 0.88[0.67–1.17], p = 0.38) and similar results were obtained when considering separately patients receiving clopidogrel (adjusted OR[95%CI] = 1.21[0.86–1.69], p = 0.29) or ticagrelor (adjusted OR[95%CI] = 1.17[0.69–2], p = 0.56).
In patients receiving DAPT for coronary artery disease, p-LCR does not impact platelet reactivity. Larger platelets did not influence the prevalence of high-on treatment platelet reactivity with the antiplatelet agents ASA, clopidogrel or ticagrelor.
KeywordsPlatelet larger cell ratio Platelet aggregation Dual antiplatelet therapy Clopidogrel Ticagrelor Coronary artery disease
The authors declare no conflict of interest and no funding source.
- 3.Shah RU, Henry TD, Rutten-Ramos S, Garberich RF, Tighiouart M, Bairey Merz CN.Increasing Percutaneous Coronary Interventions for ST-Segment ElevationMyocardial Infarction in the United States: Progress and Opportunity. JACC Cardiovasc Interv. 2015;8(1 Pt B):139–46.Google Scholar
- 9.Verdoia M, Schaffer A, Barbieri L, et al. Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials. J Cardiovasc Pharmacol. 2014;63:339–50.CrossRefPubMedGoogle Scholar
- 16.Morris MW, Davey FR. Basic examination of blood. In: Henry JB, editor. Clinical diagnosis and management by laboratory methods. USA: Saunders Company; 2001. p. 451–79.Google Scholar
- 24.Lee DH, Kim MH, Guo LZ, Park MK, Yi SJ. Lower loading dose of prasugrel compared with conventional loading doses of clopidogrel and prasugrel in Korean patients undergoing elective coronary angiography: a randomized controlled study evaluating pharmacodynamic efficacy. Korean Circ J. 2014;44:386–93.PubMedCentralCrossRefPubMedGoogle Scholar
- 26.De Luca G, Suryapranata H, Stone GW, et al. Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials. J Am Coll Cardiol. 2006;47:685–6.CrossRefPubMedGoogle Scholar
- 34.De Luca G, Verdoia M, Cassetti E, et al. Novara atherosclerosis study (NAS) group. Mean platelet volume is not associated with platelet reactivity and the extent of coronary artery disease in diabetic patients. Blood Coagul Fibrinolysis. 2013;24:619–24Google Scholar
- 38.Sachdev R, Tiwari AK, Goel S, Raina V, Sethi M. Establishing biological reference intervals for novel platelet parameters (immature platelet fraction, high immature platelet fraction, platelet distribution width, platelet large cell ratio, platelet-X, plateletcrit, and platelet distribution width) and their correlations among each other. Indian J Pathol Microbiol. 2014;57:231–5.CrossRefPubMedGoogle Scholar